Acalabrutinib (Calquence) for previously untreated chronic lymphocytic leukemia - Details (Calquence) (Last Updated: Jan 25, 2021)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indication
Brand Name:
Calquence
Manufacturer:
AstraZeneca Canada Inc.
Submission Type:
Initial